Product Description
Mechanisms of Action: P-gp Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novelion Therapeutics
Company Location: VANCOUVER A1 V6B 0M3
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Healthy Volunteers|Ovarian Cancer|Breast Cancer|Anesthesia Related|Peritoneal Cancer|Lung Cancer|Glioma|Fallopian Tube Cancer|Cervical Cancer|Neuralgia|Neuropathic Pain|Alzheimer Disease|Adrenocortical Carcinoma
Phase 1: Wilms Tumor|Sarcoma|Breast Cancer|Ovarian Cancer|Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT04603066 | P2 |
Completed |
Neuropathic Pain|Neuralgia |
2023-10-21 |
|
| 11C_TQD_ONKO | P2 |
Completed |
Glioma|Breast Cancer |
2016-08-31 |
|
| Pgp_TQD_Alzheimer | P2 |
Terminated |
Alzheimer Disease |
2016-05-13 |
|
| Polymorphisms 11C-inhibitor | P2 |
Terminated |
Healthy Volunteers |
2015-09-29 |